BH.IMMUN&BIO | CAPLIN POINT | BH.IMMUN&BIO/ CAPLIN POINT |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 22.9 | - | View Chart |
P/BV | x | 1.5 | 5.4 | 27.8% | View Chart |
Dividend Yield | % | 0.0 | 0.3 | - |
BH.IMMUN&BIO CAPLIN POINT |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
CAPLIN POINT Mar-23 |
BH.IMMUN&BIO/ CAPLIN POINT |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 856 | 6.1% | |
Low | Rs | 21 | 575 | 3.6% | |
Sales per share (Unadj.) | Rs | 10.3 | 193.2 | 5.3% | |
Earnings per share (Unadj.) | Rs | -3.9 | 49.7 | -7.8% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 55.6 | -6.8% | |
Dividends per share (Unadj.) | Rs | 0 | 4.50 | 0.0% | |
Avg Dividend yield | % | 0 | 0.6 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 245.7 | 8.3% | |
Shares outstanding (eoy) | m | 43.18 | 75.90 | 56.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 3.7 | 94.5% | |
Avg P/E ratio | x | -9.4 | 14.4 | -65.1% | |
P/CF ratio (eoy) | x | -9.5 | 12.9 | -73.8% | |
Price / Book Value ratio | x | 1.8 | 2.9 | 60.8% | |
Dividend payout | % | 0 | 9.1 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 54,308 | 2.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 1,361 | 11.1% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 14,667 | 3.0% | |
Other income | Rs m | 11 | 565 | 1.9% | |
Total revenues | Rs m | 457 | 15,233 | 3.0% | |
Gross profit | Rs m | -161 | 4,406 | -3.6% | |
Depreciation | Rs m | 2 | 450 | 0.4% | |
Interest | Rs m | 71 | 8 | 905.1% | |
Profit before tax | Rs m | -223 | 4,514 | -4.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 744 | -7.6% | |
Profit after tax | Rs m | -166 | 3,770 | -4.4% | |
Gross profit margin | % | -36.0 | 30.0 | -119.9% | |
Effective tax rate | % | 25.3 | 16.5 | 153.4% | |
Net profit margin | % | -37.3 | 25.7 | -145.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 15,545 | 2.3% | |
Current liabilities | Rs m | 940 | 2,680 | 35.1% | |
Net working cap to sales | % | -130.6 | 87.7 | -148.8% | |
Current ratio | x | 0.4 | 5.8 | 6.6% | |
Inventory Days | Days | 85 | 70 | 121.9% | |
Debtors Days | Days | 1,135 | 10 | 11,577.8% | |
Net fixed assets | Rs m | 1,262 | 6,231 | 20.3% | |
Share capital | Rs m | 432 | 898 | 48.1% | |
"Free" reserves | Rs m | 450 | 17,754 | 2.5% | |
Net worth | Rs m | 882 | 18,651 | 4.7% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 21,776 | 7.4% | |
Interest coverage | x | -2.2 | 579.7 | -0.4% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.7 | 40.9% | |
Return on assets | % | -5.9 | 17.3 | -34.1% | |
Return on equity | % | -18.9 | 20.2 | -93.3% | |
Return on capital | % | -17.2 | 24.2 | -71.1% | |
Exports to sales | % | 0 | 32.8 | 0.0% | |
Imports to sales | % | 14.5 | 1.7 | 872.9% | |
Exports (fob) | Rs m | NA | 4,804 | 0.0% | |
Imports (cif) | Rs m | 65 | 243 | 26.6% | |
Fx inflow | Rs m | 0 | 4,804 | 0.0% | |
Fx outflow | Rs m | 65 | 243 | 26.6% | |
Net fx | Rs m | -65 | 4,561 | -1.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 2,714 | 4.0% | |
From Investments | Rs m | 5 | -2,176 | -0.2% | |
From Financial Activity | Rs m | -147 | -282 | 52.2% | |
Net Cashflow | Rs m | -34 | 268 | -12.5% |
Indian Promoters | % | 59.3 | 70.6 | 83.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 4.4 | - | |
FIIs | % | 0.0 | 3.3 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 29.4 | 138.7% | |
Shareholders | 35,313 | 81,409 | 43.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | CAPLIN POINT | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -1.85% | 0.31% |
1-Month | -2.23% | 1.41% | 0.08% |
1-Year | 28.97% | 94.83% | 54.11% |
3-Year CAGR | -13.27% | 38.35% | 14.46% |
5-Year CAGR | 30.36% | 30.38% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the CAPLIN POINT share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of CAPLIN POINT the stake stands at 70.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of CAPLIN POINT.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
CAPLIN POINT paid Rs 4.5, and its dividend payout ratio stood at 9.1%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of CAPLIN POINT.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.